The association of mRNA expression of predicted target genes (PDCD6, GNG5, PHF6, MAL2, SLC25A15, PTDSS1) with clinicopathological parameters of BLCA patients were analyzed by UALCAN, containing BLCA individual cancer stages and molecular subtypes (Figures 8 and 9). This evidence concerns the gene MAL2 and bladder transitional cell carcinoma.